Absci Cash Flow Statement
NASDAQ: ABSIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
10.16+1.22 (+13.65%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Absci free cash flow
In fiscal 2025, Absci generated -$92.9 million of operating cash flow and spent $1.1 million on capital expenditures. That left free cash flow of -$94.0 million, a free-cash-flow margin of -3358.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Absci cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M | -14.35M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 11.74M | 13.39M | 14.00M | 13.04M | 6.65M | 1.13M |
| Stock-Based Compensation | 18.32M | 19.45M | 11.42M | 12.54M | 10.61M | 420.00K |
| Change in Working Capital | 729.00K | 462.00K | 3.84M | 942.00K | -7.34M | 1.32M |
| Operating Cash Flow | -92.92M | -72.40M | -64.64M | -81.34M | -60.60M | -10.97M |
| Capital Expenditures | -1.11M | -404.00K | -860.00K | -16.18M | -38.05M | -2.18M |
| Investing Cash Flow | -50.16M | -41.58M | 81.94M | -126.98M | -67.38M | -2.17M |
| Debt Repaid | -3.12M | -3.39M | -3.01M | -4.65M | -1.60M | -500.00K |
| Financing Cash Flow | 105.95M | 82.53M | -4.48M | 5.24M | 336.19M | 70.97M |
| Net Change in Cash | -37.14M | -31.45M | 12.82M | -203.08M | 208.22M | 57.83M |
| Free Cash Flow | -94.03M | -72.81M | -65.50M | -97.51M | -98.64M | -13.15M |
This table shows 6 annual periods of Absci's cash flow statement, from FY 2025 back to FY 2020, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABSI's reporting calendar. What is a cash flow statement?